top of page
Our pipeline
Mablink builds its pipeline on the topoisomerase-I inhibitor exatecan as a payload for current developments
Our pipeline strategy
The PSARLink™ platform being especially suited for the use of moderately potent ADC payloads, Mablink builds its pipeline on the topoisomerase-I (topo-I) inhibitor exatecan as a payload, for current developments.
The topo-I inhibitor family (including irinotecan and topotecan) is active against a wide range of tumors (including breast, colorectal and ovarian cancer) and is better tolerated than tubulin inhibitors and DNA alkylators, hence a broader therapeutic window (confirmed clinically by Enhertu®).
Mablink focuses its development on worst prognosis indications.
Hematology
Acute myeloid leukemia (AML)
MBK-101
Discovery
Ready for partnering
Preclinical
Phase1
Phase 2
FIH in 2024
Non-Hodgkin's lymphoma (NHL)
MBK-102
Discovery
Ready for partnering
Preclinical
Phase1
Phase 2
Partnered pipeline
Emergence Therapeutics' lead program combines a highly specific antibody with Mablink's PSARLink™ technology to target Nectin-4 – an important target for a broad range of cancers which has been clinically validated as an ADC target by enfortumab vedotin, now approved for the treatment of urothelial cancers by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
See Press Release.
bottom of page